BACKGROUND: The alpha1-adrenergic receptors (alpha1-ARs) play a key role in cardiovascular homeostasis. However, the functional role of alpha1-AR subtypes in vivo is still unclear. The aim of this study was to evaluate the cardiovascular influences of alpha1b-AR. METHODS AND RESULTS: In transgenic mice lacking alpha1-AR (KO) and their wild-type controls (WT), we evaluated blood pressure profile and cardiovascular remodeling induced by the chronic administration (18 days via osmotic pumps) of norepinephrine, angiotensin II, and subpressor doses of phenylephrine. Our results indicate that norepinephrine induced an increase in blood pressure levels only in WT mice. In contrast, the hypertensive state induced by angiotensin II was comparable between WT and KO mice. Phenylephrine did not modify blood pressure levels in either WT or KO mice. The cardiac hypertrophy and eutrophic vascular remodeling evoked by norepinephrine was observed only in WT mice, and this effect was independent of the hypertensive state because it was similar to that observed during subpressor phenylephrine infusion. Finally, the cardiac hypertrophy induced by thoracic aortic constriction was comparable between WT and KO mice. CONCLUSIONS: Our data demonstrate that the lack of alpha1b-AR protects from the chronic increase of arterial blood pressure induced by norepinephrine and concomitantly prevents cardiovascular remodeling evoked by adrenergic activation independently of blood pressure levels.
BACKGROUND: The alpha1-adrenergic receptors (alpha1-ARs) play a key role in cardiovascular homeostasis. However, the functional role of alpha1-AR subtypes in vivo is still unclear. The aim of this study was to evaluate the cardiovascular influences of alpha1b-AR. METHODS AND RESULTS: In transgenic mice lacking alpha1-AR (KO) and their wild-type controls (WT), we evaluated blood pressure profile and cardiovascular remodeling induced by the chronic administration (18 days via osmotic pumps) of norepinephrine, angiotensin II, and subpressor doses of phenylephrine. Our results indicate that norepinephrine induced an increase in blood pressure levels only in WT mice. In contrast, the hypertensive state induced by angiotensin II was comparable between WT and KO mice. Phenylephrine did not modify blood pressure levels in either WT or KO mice. The cardiac hypertrophy and eutrophic vascular remodeling evoked by norepinephrine was observed only in WT mice, and this effect was independent of the hypertensive state because it was similar to that observed during subpressor phenylephrine infusion. Finally, the cardiac hypertrophy induced by thoracic aortic constriction was comparable between WT and KO mice. CONCLUSIONS: Our data demonstrate that the lack of alpha1b-AR protects from the chronic increase of arterial blood pressure induced by norepinephrine and concomitantly prevents cardiovascular remodeling evoked by adrenergic activation independently of blood pressure levels.
Authors: C Vecchione; M T Gentile; A Aretini; G Marino; R Poulet; A Maffei; F Passarelli; A Landolfi; A Vasta; G Lembo Journal: Diabetologia Date: 2007-02-06 Impact factor: 10.122
Authors: Nicoletta Potenza; Carmine Vecchione; Antonella Notte; Assunta De Rienzo; Annamaria Rosica; Lisa Bauer; Andrea Affuso; Mario De Felice; Tommaso Russo; Roberta Poulet; Giuseppe Cifelli; Gabriella De Vita; Giuseppe Lembo; Roberto Di Lauro Journal: EMBO Rep Date: 2005-05 Impact factor: 8.807
Authors: Jason U Tilan; Lindsay M Everhart; Ken Abe; Lydia Kuo-Bonde; Dan Chalothorn; Joanna Kitlinska; Mary Susan Burnett; Stephen E Epstein; James E Faber; Zofia Zukowska Journal: FASEB J Date: 2013-03-01 Impact factor: 5.191
Authors: John M Dopp; Alexei V Agapitov; Christine A Sinkey; William G Haynes; Bradley G Phillips Journal: Am J Hypertens Date: 2013-02-26 Impact factor: 2.689